NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquartered in Zurich, Switzerland.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-2.51M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -25.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-11.28 |
| Price-to-Book | 616.24 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.35M |
| Float | $2.05M |
| % Insiders | 61.83% |
| % Institutions | 3.54% |
Volatility is currently expanding